Welcome
Support Centre
12 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
The potential role of B-Type natriuretic peptide (BNP) and high-sensitivity troponin t(hs-tnt) pre-screening by GPs to better target rapid access chest pain clinic referrals
ISRCTN ISRCTN67362546
ClinicalTrials.gov identifier
Public title The potential role of B-Type natriuretic peptide (BNP) and high-sensitivity troponin t(hs-tnt) pre-screening by GPs to better target rapid access chest pain clinic referrals
Scientific title The potential role of B-Type natriuretic peptide (BNP) and high-sensitivity troponin t(hs-tnt) pre-screening by GPs to better target rapid access chest pain clinic referrals: a prospective observational longitudinal cohort study
Acronym N/A
Serial number at source GEO003
Study hypothesis Rapid access chest pain clinics (RACPCs) are being established throughout the NHS. However they are costly, especially since at least 50% of referrals turn out to have non-cardiac pain. A pre-screening test before RACPC referral might reduce referrals, save money and relieve unnecessary patient anxiety. The pre-screening test which might fulfil this function is B-Type natriuretic peptide (BNP) and high-sensitivity troponin t(hs-tnt). We wish to formally study how accurate a pre-screening test for BNP and high-sensitivity troponin t(hs-tnt) would be in safely identifying that a potential RACPC referral was unnecessary. We will do this by measuring BNP and high-sensitivity troponin t(hs-tnt) in 500 of the patients who are currently referred to the RACPCs in Tayside. We will also see whether BNP and high-sensitivity troponin t(hs-tnt) is able to accurately predict which patients will suffer a cardiovascular event in the year after their RACPC referral. Data in other populations make this appear a very likely prospect. We will also do a full assessment to assess all the other knock on consequences if GPs were to use BNP and high-sensitivity troponin t(hs-tnt) to select their RACPC referrals.
Lay summary
Ethics approval Tayside Local Research Ethics Committee approved in 10/2005 (ref: 05/S1402/49)
Study design Prospective observational longitudinal cohort study
Countries of recruitment United Kingdom
Disease/condition/study domain Cardiac chest pain
Participants - inclusion criteria 1. Patients presenting to the rapid Access Chest Pain Clinic with Cardiac Chest Pain
2. Aged 20 - 93 years, both male and female
Participants - exclusion criteria Patients with non-cardiac chest pain
Anticipated start date 01/03/2007
Anticipated end date 31/08/2009
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 625
Interventions 625 patients attending Rapid Access Chest Pain Clinics in Tayside were recruited into the study over a two year period. Each patient had demographic data, a near patient BNP and high-sensitivity troponin t(hs-tnt) level (Biosite®), clinical and laboratory measurements documented. The initial diagnosis was considered positive for ischaemic heart disease (IHD) if the patient had a positive troponin T or was referred for angiography. All patients were then followed up one year after their initial RACPC attendance using hospital medical records, primary care records and telephone calls to document further RACPC attendance, hospitalisations for chest pain and survival data.
Primary outcome measure(s) Negative predictive value of BNP compared to final clinical diagnosis and troponin T result
Secondary outcome measure(s) 12 month follow-up for hospital free survival based on initial BNP and high-sensitivity troponin t(hs-tnt) level
Sources of funding Chest Heart and Stroke Scotland (UK) (ref: Res07/A105)
Trial website
Publications
Contact name Dr  Jacob  George
  Address Department of Clinical Pharmacology
Centre for Cardiovascular and Lung Biology
Mailbox 2, Level 7
Ninewells Hospital
  City/town Dundee
  Zip/Postcode DD1 9SY
  Country United Kingdom
  Tel +44 (0)1382 632180
  Fax +44 (0)1382 644972
  Email j.george@dundee.ac.uk
Sponsor University of Dundee (UK)
  Address Nethergate
  City/town Dundee
  Zip/Postcode DD1 4HN
  Country United Kingdom
  Sponsor website: http://www.dundee.ac.uk/
Date applied 29/12/2009
Last edited 31/05/2011
Date ISRCTN assigned 06/04/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central